25I-NBF
25I-NBF is a synthetic psychedelic of the substituted phenethylamine class, specifically an N-benzylated derivative of 2C-I.1 It acts as a potent partial agonist at the 5-HT2A serotonin receptor2 and has been investigated in radiolabelled form as a potential ligand for brain imaging via positron emission tomography.3 Pharmacological evidence suggests it is considerably less potent than its structural relative 25I-NBOMe.1 It was briefly available as a research chemical before being banned in several countries.
Contents
Dosage & Duration
Subjective Effects
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
25I-NBF acts as a highly potent partial agonist at the human 5-HT2A receptor, with signaling bias towards the β-arrestin 2 coupled pathway.2
Pharmacokinetics
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Serotonergic psychedelics, Other 5-HT2A agonists
Harm Potential
History & Culture
25I-NBF emerged as part of the broader NBOMe and NBF series of N-benzyl phenethylamine derivatives developed for research purposes.31 The compound has been investigated in its carbon-11 radiolabelled form (designated Cimbi-21) as a…
Legality
By Country
References
Source Pages
Citations
- (n.d.). Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists. https://pmc.ncbi.nlm.nih.gov/articles/PMC3963123/123
- (December 2020). Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT<sub>2A</sub>R through simultaneous use of β-arrestin 2 and miniGα<sub>q</sub> bioassays. Biochemical Pharmacology, 182. https://doi.org/10.1016/j.bcp.2020.11425112
- (April 2011). Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers. European Journal of Nuclear Medicine and Molecular Imaging, 38(4), 681–693. https://doi.org/10.1007/s00259-010-1686-8123
- (2015). Läkemedelsverkets föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika (HSLF-FS 2015:35). Läkemedelsverket (Swedish Medical Products Agency). https://lagen.nu/hslf-fs/2015:3512
- (2014). The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014 (SI 2014/1106), Article 3. UK Parliament. https://www.legislation.gov.uk/uksi/2014/1106/made1
- (1971). Misuse of Drugs Act 1971, Schedule 4 — Prosecution and Punishment of Offences. UK Parliament. https://www.legislation.gov.uk/ukpga/1971/38/schedule/41
- (n.d.). 21 U.S. Code § 813 — Treatment of controlled substance analogues. Cornell Legal Information Institute. https://www.law.cornell.edu/uscode/text/21/8131
Further Reading
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 25I-NBF article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.